The importance of early immunotherapy in patients with faciobrachial dystonic seizures.

Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR, Faciobrachial Dystonic Seizures Study Group. · 2018

Read The importance of early immunotherapy in patients with faciobrachial dystonic seizures. by Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR, Faciobrachial Dystonic Seizures Study Group. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5837230.txt.

Introduction

Thompson and co-authors report the largest series yet of faciobrachial dystonic seizures, an antibody-driven epilepsy. Their study appeared in Brain. The seizures grip the face and arm in brief jerks. They trace to LGI1 antibodies and often precede memory loss.

The team followed 103 patients from an international network. Seizure drugs alone rarely stopped the attacks. Immunotherapy ended them in most patients. Each delay shrank the odds of success. Patients treated before thinking problems set in kept better long-term function. The authors argue these seizures are a warning shot worth urgent treatment.

Catalog record

CREATORThompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR, Faciobrachial Dystonic Seizures Study Group.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5837230

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The importance of early immunotherapy in patients with faciobrachial dystonic seizures By Julia Thompson, Mian Bi, Andrew G Murchison, Mateusz Makuch, Christian G Bien, Kon Chu, Pue Farooque, Jeffrey M Gelfand, Michael D Geschwind, Lawrence J Hirsch, Ernest Somerville, Bethan Lang Published in: Brain DOI: 10.1093/brain/awx323 ABSTRACT Faciobrachial dystonic seizures (FBDS) are the first adult-onset autoantibody-mediated epilepsy. Thompson et al. describe 103 patients with FBDS, and show that seizures are responsive to immunotherapy, with early seizure cessation reducing long-term disability and preventing cognitive impairment. Potential pathogenic mechanisms include complement fixation and LGI1-ADAM22 complex internalisation. INTRODUCTION Autoantibodies to leucine-rich glioma-inactivated 1 (LGI1) are associated with a limbic encephalitis. This presents with the subacute onset of frequent seizures and cognitive impairment, characterized by amnesia, confusion and executive dysfunction, often with hyponatraemia and medial temporal lobe high-signal on T2-weighted MRI (Thieben et al., 2004; Vincent et al., 2004; Irani et al., 2010; Lai et al., 2010). Patients improve with immunotherapies, but frequently have significant residual cognitive deficits (Butler et al., 2014; Ariño et al., 2016; Finke et al., 2017). In addition, LGI1 antibodies are associated with a highly specific focal seizure semiology termed faciobrachial dystonic seizures (FBDS) (Irani et al., 2008, 2011, 2013; Flanagan et al., 2015). Recognition of this characteristic semiology permits an accurate clinical diagnosis without ancillary testing (Sen et al., 2014). Experiences from several small studies have suggested that FBDS appear preferentially responsive to immunotherapy over antiepileptic drugs (AEDs) (Irani et al., 2008, 2011, 2013; Flanagan et al., 2015; Navarro et al., 2016; van Sonderen et al., 2016). However, these studies provided limited quantification of treatment timings and minimal follow-up. Moreover, some untreated patients demonstrated improvements (Szots et al., 2014). Therefore, FBDS represent an increasingly recognized condition about which the impacts of treatment type and delay have received little attention, even in the largest dedicated series of 29 patients (Irani et al., 2011). Furthermore, there has been no systematic characterization of patients with FBDS without cognitive impairment. This may be especially informative as FBDS often predate the onset of cognitive impairment (Irani et al., 2011, 2013; van Sonderen et al., 2016). Here, we present a series of 103 patients with FBDS and LGI1 antibodies. We compare those with and without cognitive impairment, quantify the relative effects of AEDs and immunotherapy, address the hypothesis that early immunotherapy administration may prevent progression to cognitive impairment (Irani et al., 2011), and explore potential pathogenic mechanisms of the LGI1 antibodies. MATERIALS AND METHODS Standardized questionnaires (Supplementary Table 1) were distributed to an international network of clinicians who discussed patients with the Oxford Autoimmune Neurology Group between 2008 and 2013. Consecutive patients with a diagnosis of FBDS and serum LGI1 antibodies were included. Data from 103 patients described clinical and investigation features, treatment timings and modified Rankin Scale (mRS) outcomes at 12 (n = 96), 24 (n = 88) and 48 (n = 55) months. Cognitive impairment was based on the clinical impression, and was well supported by available cognitive testing (Supplementary Fig. 1A). Patients and consultees underwent informed consent (approval REC16/YH/0013). Statistical analyses were performed in R 3.2.3 and RStudio Version 0.99.491 (Supplementary material). LGI1-antibody determination with a novel flow-cytometry assay (FCA) was developed to quantify serum IgG-subclass deposition on live HEK293T cells that stably-express membrane-tethered LGI1-EGFP. ADAM22 co-transfection and soluble LGI1 were used for internalization experiments (Supplementary material). RESULTS Demographics, phenotype and tumours Overall, 64 of 103 (62%) patients were male, with a normal distribution centred on a median age of 64 years, and a range (22–92 years) that spared children (Fig. 1A). Only eight (8%) patients had an identified tumour, each a different type (Supplementary Table 2). Most patients with FBDS from the UK and USA were Caucasian, and no patients were of Afro-Caribbean descent (Fig. 1B). In agreement with previous smaller reports (Andrade et al., 2011; Irani et al., 2011, 2013; Shin et al., 2013; Navarro et al., 2016; van Sonderen et al., 2016; Aurangzeb et al., 2017), FBDS showed a high maximal frequency (median 32 per day, range 2–400), short duration (1–5 s in 74% of patients) and involvement of arm (99%), face (89%) and leg (36%) (Supplementary Fig. 1B and C). Examples are shown in Supplementary Videos 1 and 2. [Figure: Clinical characteristics and investigation findings in 103 patients with faciobrachial dystonic seizures. (A) Age and gender distribution. The eight patients with known tumours are shown (details in Supplementary Table 2). (B) Ethnicity in patients with FBDS closely resembled the local population in both UK and USA, except for the absence of Afro-Caribbean cases. (C) Red-coloured boxes highlight abnormalities in MRI, ictal- and interictal (inter)- EEG (epileptiform features, diffuse and focal slowing), serum sodium, and CSF from patients with (n = 81) and without (n = 22) cognitive impairment. Sum represents the total number of abnormalities per patient. BG = basal ganglia; CI = cognitive impairment; Temp = temporal lobe. **P < 0.01, ***P < 0.001, ****P < 0.0001 (Welch’s unequal variance test for the Sum, Fisher’s exact test used for all others).] Differences between patients with and without cognitive impairment Compared to patients identified prior to the 2011 description of FBDS, those identified after 2011 were less likely to have cognitive impairment [3/46 (7%) versus 19/57 (33%); P = 0.013, Fisher’s], and received earlier immunotherapy (median 45 versus 112 days, P = 0.0036, Mann-Whitney U-test). A comparison of FBDS patients with (n = 81) and without cognitive impairment (n = 22; Supplementary Table 2) revealed marked similarities in demographics, frequent additional seizure semiologies and other clinical features, except hallucinations, mood and sleep disturbances, which were only observed in patients with cognitive impairment. Medial temporal lobe T2-hyperintensities (mostly involving the amygdala and hippocampus, P < 0.0001), temporal and frontal lobe ictal EEG changes (P = 0.0096), and serum hyponatraemia (P < 0.0001) were almost only observed in patients with cognitive impairment (Fig. 1C). Overall, patients with cognitive impairment had more abnormal investigations than those with FBDS alone (mean 2.12 versus 0.77, P < 0.0001, Fig. 1C). Treatments administered and side effects In total, 99 (96%) patients were administered AEDs (median = 2, range 1–10), most commonly levetiracetam (n = 69), sodium valproate (n = 37), phenytoin (PHT, n = 32), and carbamazepine (CBZ, n = 26). Ninety-eight (95%) patients received immunotherapy (Supplementary Table 2): the most common immunotherapy regimes were corticosteroids alone (n = 36; 37%), corticosteroids plus intravenous immunoglobulins (IVIG, n = 33; 34%), corticosteroids plus plasma exchange (PLEX, n = 12; 12%), and all three agents (n = 12; 12%). Strikingly, cutaneous reactions were seen in a total of 29 (29%) patients on AEDs, including five with Stevens-Johnson syndrome (Supplementary Fig. 1D). These reactions occurred across ethnicities, and were significantly associated with exposure to CBZ (48% of patients with cutaneous reactions, P = 0.0099) and to PHT (50%, P = 0.03; Supplementary Table 3). Side effects of immunotherapy were also common, in 43 (44%) patients, and most frequently affected mood (n = 21) and the musculoskeletal system (n = 11, myopathy, tendon rupture and osteoporosis). Five deaths were attributed to complications from PLEX [acute respiratory distress syndrome (n = 2), sepsis (n = 2) and pulmonary emboli (n = 1)]. Cessation of FBDS: a comparison of antiepileptic

Read the complete text